PIG Stock Chart & Stats
€8.73
-€0.27(-2.98%)
At close: 4:00 PM EDT
€8.73
-€0.27(-2.98%)
Day’s Range― - ―
52-Week Range€7.82 - €20.41
Previous CloseN/A
Volume0.00
Average Volume (3M)9.00
Market Cap
€1.72B
Enterprise Value€4.45K
Total Cash (Recent Filing)€399.70M
Total Debt (Recent Filing)€3.29B
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Nov 11, 2026EPS Estimate
0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.51
Shares Outstanding138,769,240
10 Day Avg. Volume27
30 Day Avg. Volume9
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.66
Price to Sales (P/S)0.45
P/FCF Ratio13.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.58Price Target Upside67.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.85
Revenue Forecast (FY)€3.52B
Bulls Say, Bears Say
Bulls Say
Market Share And Service-Level GainsOutperforming declining categories while improving service levels strengthens retailer relationships and distribution reliability. These gains can support durable share retention and improve Perrigo’s competitive position across private-label and branded self-care markets.
Positive Cash Generation And Debt ReductionPositive free cash flow provides internal funding despite accounting losses, while divestiture proceeds used for debt repayment can reduce interest burden and financial risk. Continued cash generation and deleveraging would improve flexibility for investment and restructuring.
Operational Savings And Innovation PipelineA scalable innovation pipeline can broaden launches across Perrigo’s platforms, while targeted savings may rebuild margins over time. Together, these initiatives address execution weaknesses and create a foundation for more efficient, diversified growth.
Bears Say
Persistent Revenue DeclinesShrinking sales across core categories indicate weaker demand and retailer inventory pressure, limiting operating leverage. Prolonged softness could reduce manufacturing utilization, weaken negotiating power, and make the company’s recovery dependent on uncertain innovation and distribution gains.
Margin Compression And Earnings WeaknessLower gross and operating margins show that reduced volumes and cost pressures are affecting profitability, while under-absorption adds a significant earnings burden. Persistent margin weakness could constrain reinvestment and delay restoration of sustainable operating profits.
Elevated LeverageSubstantial debt relative to equity leaves Perrigo exposed to interest costs and reduces financial flexibility while profitability is weak. Although divestiture proceeds have lowered borrowings, leverage remains a material constraint on investment, dividends, and resilience.
Perrigo Company News
PIG FAQ
What was Perrigo Company plc’s price range in the past 12 months?
Perrigo Company plc lowest stock price was €7.82 and its highest was €20.41 in the past 12 months.
What is Perrigo Company plc’s market cap?
Perrigo Company plc’s market cap is €1.72B.
When is Perrigo Company plc’s upcoming earnings report date?
Perrigo Company plc’s upcoming earnings report date is Nov 11, 2026 which is in 75 days.
How were Perrigo Company plc’s earnings last quarter?
Perrigo Company plc released its earnings results on Aug 05, 2026. The company reported €0.433 earnings per share for the quarter, beating the consensus estimate of €0.336 by €0.097.
Is Perrigo Company plc overvalued?
According to Wall Street analysts Perrigo Company plc’s price is currently Undervalued.
Does Perrigo Company plc pay dividends?
Perrigo Company plc does not currently pay dividends.
What is Perrigo Company plc’s EPS estimate?
Perrigo Company plc’s EPS estimate is 0.45.
How many shares outstanding does Perrigo Company plc have?
Perrigo Company plc has 138,769,240 shares outstanding.
What happened to Perrigo Company plc’s price movement after its last earnings report?
Perrigo Company plc reported an EPS of €0.433 in its last earnings report, beating expectations of €0.336. Following the earnings report the stock price went up 18.254%.
Which hedge fund is a major shareholder of Perrigo Company plc?
Currently, no hedge funds are holding shares in DE:PIG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Perrigo Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€14.58 (67.04% Upside)
€14.58 (67.04% Upside)
Blogger Sentiment
Bullish
DE:PIG Sentiment 80%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.03%
12-Months-Change
Fundamentals
Return on Equity
8.08%
Trailing 12-Months
Asset Growth
-24.61%
Trailing 12-Months
Company Description
Perrigo Company plc
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
PIG Company Deck
PIG Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear operational progress and strategic actions against ongoing top-line and margin pressures. Positive indicators include market share gains, substantial service-level improvements, a recovering Infant Formula business (+23% sales, +$60M operating income), acceleration of a scalable innovation pipeline, targeted cost-savings ($80–$100M program) and the use of $359M divestiture proceeds to reduce debt. Offsetting these positives were a 3%+ decline in net sales, 250 basis points of gross margin compression, notable retailer destocking (≈1.8% headwind), specialty segment weakness and an expected ~$0.60 EPS headwind in 2026 from under-absorption. Management maintained full-year guidance and emphasized that results are weighted to a stronger second half, signaling cautious optimism but acknowledging remaining execution and demand risks.View all DE:PIG earnings summariesPIG Stock 12 Month Forecast
Average Price Target
€14.58
▲(67.04% Upside)
Technical Analysis
Viatris
―
Supernus Pharmaceuticals
―
Teva Pharmaceutical
―
Indivior
―
Amneal Pharmaceuticals
―